Bibliography
- Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29
- Cassier PA, Dufresne A, Fayette J, et al. Emerging drugs for the treatment of soft tissue sarcomas. Expert Opin Emerging Drugs 2007;12:139-53
- Practice guidelines in oncology: soft tissue sarcoma, version 3. 2007. US National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf [Last accessed 19 December 2007]
- Kasper B, Gil T, Awada A. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol 2007;19:336-40
- Neilsen OS, Dombernowsky P, Mouridsen H, et al. High dose eprirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft-tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 1998;78:1634-9
- Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte–macrophage colony-stimulating factor in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-84
- Bokemeyer C, Franzke A, Hartmann JT, et al. A Phase I/II study of sequential, dose-escalated high-dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221-7
- Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998;21:317-21
- Brennan MF, Casper ES, Harison L. Soft tissue sarcoma. In: De Vita V, Hellman S, Rosenberg SA, editors, Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997. p. 1738-88
- Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9
- D'Adamo DR, Anderson S, Albritton K, et al. Cardiac toxicity in a Phase II study of doxorubicin and bevacizumab for pts with metastatic soft tissue sarcomas [abstract 2004 9012]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- Verschraegen CF, Fekrazad HM, Rabinowitz R, et al. Phase I/II study of docetaxel, gemcitabine and bevacizumab in patients with advanced or recurrent soft tissue sarcoma [abstract 10056]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- Sleijfer S, Papai Z, Le Cesne A, et al. Phase II study of pazopanib (GW786034) in patients with relapsed or refractory soft tissue sarcoma: EORTC 62043 [abstract 10031]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- D'Adamo DR, Keohan M, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients with non-GIST sarcomas (CETP study #7060) [abstract 10001]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- Clinical Trials.gov. A service of the US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/results?termsoft+tissue+sarcoma [Last accessed 4 December 2007]
- Biron P, Reichardt P, Grosso F, et al. A Phase II study of gimatecan as salvage treatment in patients with advanced or metastatic soft tissue sarcoma relapsing after anthracycline-based chemotherapy regimens [abstract 10063]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31
- Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-63
- Guan Y, Sakai R, Rinehart KL, Wang AH. Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993;10:793-818
- Martinez N, Sánchez-Beato M, Carnero A, et al. Transcriptional signature of 743 (Yondelis, trabectedin) in human sarcoma cells explanted from chemo-naïve patients. Mol Cancer Ther 2005;4:814-23
- Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-309
- Aune GJ, Furuta T, Pommier Y. 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 2002;13:545-55
- Zewail-Foote M, Hurley LH. 743: a minor groove alkylator that bends DNA towards the major groove. J Med Chem 1999;42:2493-7
- Trabectedin: 743, -743, ET 743, ET-743, NSC 684766. Drugs R&D 2006;7:317-28
- Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug -743. Proc Natl Acad Sci USA 2000;97:2493-7
- Jin S, Gorfajn B, Faircloth G, Scotto KW. 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000;97:6775-79
- Friedman D, Hu Z, Kolb EA, et al. -743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-81
- Jimeno J, Aracil M, Tercero JC. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med 2006;4:3
- Moore BM II, Seaman FC, Hurley LH. NMR-based model of anecteinascidin 743-DNA adduct. J Am Chem Soc 1997;119:5475-6
- Takebayashi Y, Goldwasser F, Urusaki Y, et al. 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase 1 expression. Clin Cancer Res 2001;7:85-91
- Erba E, Bergamschi D, Bassano L, et al. -743 (ET-743), a natural marine compound with a unique method of action. Eur J Cancer 2001;37:97-105
- Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous repair regulate DNA double helix stand break formation by the antitumor aklylator -743. Proc Natl Acad Sci USA 2007;104:13062-7
- Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of -743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-11
- Grosso F, Forni C, Frapolli R, et al. Sensitivity of myxoid-round cell liposarcoma to trabectedin may be related to a direct effect on the fusion transcript [abstract 10000]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 2007;46:867-84
- Schöffski P, Wolter P, Clement P, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007;3:381-92
- Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002;50:309-19
- van Kesteren C, Twelves C, Bowman A, et al. Clinical pharmacology of the novel marine-derived anticancer agent 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 2002;13:381-93
- Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005;23:429-36
- Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A Phase I and pharmacokinetic study of -743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8:75-85
- Brain EG. Safety and efficacy of ET-743: the French experience. Anticancer Drugs 2002;13(Suppl 1):S11-4
- Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-42
- Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of -743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-65
- van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent 743 in a Phase I dose-finding study. Clin Cancer Res 2000;6:4725-32
- Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis TM (ET-743) administered as an infusion over 1 hour or 3 hours every 21 days in patients with solid tumours. Eur J Cancer 2003;39:1842-51
- Forouzesh B, Hildago M, Denis L, et al. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder administered weekly to patients with advanced cancer [abstract 94a]. Proc Am Soc Clin Oncol 2001;20:373
- Le Cesne A, Blay JY, Judson E, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-84
- Yovine A, Riofrio M, Blay JY, et al. Phase II study of -743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-9
- Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of 743 in patients with progressive sarcomas of soft tissue refractory to chemotherapy. J Clin Oncol 2004;22:1480-90
- Le Cesne A, Demetri G, Jean L, et al. Impact of Yondelis in the natural history of patients with pretreated advanced soft tissue sarcomas: long-term follow-up results [abstract 31]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 17 – 23 November 2003; Boston, MA, USA. Clin Cancer Res 2003;9(16 Pt 2):6069s-6306s
- Jimeno J, Maki R, Casali P, et al. Therapeutic impact of ET-743 (Yondelis®, trabectidin) a new marine derived compound in Sarcoma. Curr Opin Orthoped 2003;14:419-28
- Morgan JA, Le Cesne A, Chawla S, et al. Randomized Phase II study of trabectedin in patients with liposarcoma and leiomyosarcomas after failure of prior anthracyclines and ifosfamide [abstract 10060]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 2007;25(18S)
- Garcia-Carbonero R, Supko JG, Maki RG, et al. -743 for chemotherapy-naïve patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-92
- Boyle H, Favier B, Lurkin A, et al. ET 743 is an effective agent against sarcoma [abstract 20516]. ASCO 2007 Annual Proceedings Part 1. J Clin Oncol 207;25(18S)
- Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (-743) in advanced pretreated myxoid liposarcoma: a retrospective study. Lancet Oncol 2007;8:595-602
- Grosso F, Sanfilippo R, Dileo P, et al. Breaking down tumor responses by their dimensional entity in advanced STS (non-mixoid/round cell liposarcoma) treated with trabectedin may predict progression free survival [abstract 716]. 12th Annual CTOS Meeting; 2006 November 2 – 4; Venice, Italy. Alexandria, VA: Connective Tissue Oncology Society.
- Blay J, von Mehren M, Samuels BL, et al. Combination of trabectedin and doxorubicin for the treatment of patients with soft tissue sarcoma: safety and efficacy analysis [abstract 10078]. ASCO 2007 Annual Proceedings part 1. J Clin Oncol 2007;25(18S)
- Yondelis Summary of Product Characteristics SPC. EMEA 2007. Available from: http://www.emea. europa.eu/humandocs/PDFs/EPAR/yondelis/H-773-en6.pdf [Last accessed 17 December 2007]
- Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42:1484-90
- Fetterly GJ, Owen JS, Stuyckens K, et al. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemother Pharmacol 2008;62:135-47
- Yondelis (Pharmamar) SPC. Electronic Medicines Compendium (eMC). Document last updated on the eMC. 2008 January 7. Available from: http://www.emc.medicines.org. uk/emc/assets/c/html/displaydoc.asp?documentid=20457 [Last accessed 25 April 2008]
- Lopez JA, Nieto A, Demetri G, et al. Safety profile of ecteinascidin 743 (ET-743) in Phase II clinical trials (CT) in adult patients with solid tumours. ASCO 2002 Annual Proceedings [abstract 382]. Proc Am Soc Clin Oncol 2002;21:96a
- Carter NJ, Kean SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007;67:2257-76
- Schöffski P, Grosso F, Taron M, et al. DNA repair functionality as a molecular signature for sensitivity/resistance in sarcoma patients treated with trabectedin [abstract 144]. AACR Annual Meeting; 2007 April 14 – 18; Los Angeles, California, USA
- Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-24
- Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-74
- Zelek L, Yovine A, Brain E. A Phase II study of Yondelis (trabectedin, ET-743) as a 24 h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-4